Pharmac consultation: proposal on access criteria for two COVID-19 treatments

Kia ora
 
Please follow this link to the Pharmac Consultation regarding proposed access criteria for nirmatrelvir with ritonavir (Paxlovid, Pfizer PF-07321332) and molnupiravir (Lageviro, MK-4482) for the treatment of COVID-19.
 
Pharmac welcomes feedback on this proposal.

To provide feedback, please email consult@pharmac.govt.nz by 5pm on Wednesday 2nd March 2022.
 
Please circulate this email to others who may be interested.
 
Ngā mihi nui

 
Ben Graham | Therapeutic Group Manager
__________________________________________________________________
Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington 
www.pharmac.govt.nz

Back to blog entries